As per DelveInsight, total Diabetic Peripheral Neuropathy diagnosed prevalent cases are expected to reach 25,860,249 in the 7MM by 2020 from 25,332,829 in 2017. The United States is expected to account for the maximum total Painful Diabetic Peripheral Neuropathy Prevalent Cases. Moreover, a higher female disposition is observed in DPN.
The Diabetic Peripheral Neuropathy Market is expected to grow with a CAGR of 12% by 2030 attributed to increasing DPN prevalence, and introduction to gene therapies in the pipeline.
The key players in the Diabetic Peripheral Neuropathy market includes Helixmith, Aptinyx Inc., WinSanTor, Regenacy Pharmaceuticals LLC, Novaremed AG, Glenmark Pharmaceuticals, Grünenthal Group, and others.
For more details visit: https://www.delveinsight.com/blog/diabetic-peripheral-neuropathy-market-landscape/